Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA.
3 contributing indexes 4 score components composite score.
Canonical asset packet first: fundamentals, macro index exposure, entry value, and active narrative alignment. Driver rows link back to the public index that moved the score.
| Index | Driver | Reason | Weight | Condition | Contribution | As Of |
|---|---|---|---|---|---|---|
| RACI | Robotics & Automation Capex Index | research activity | 7% | research activity — tailwind Moderate signal—/100Tailwind +0.53σ | +0.041 | 2026-05-22 |
| BPHI | Biotech & Pharma Health Index | gene editing innovation | 17% | gene editing innovation — tailwind Near normal—/100Tailwind +0.13σ | +0.031 | 2026-05-22 |
| RQRI | Risk-Quality Rotation Index | risk appetite | 3% | risk appetite — tailwind Moderate signal—/100Tailwind +1.30σ | +0.028 | 2026-05-22 |
